Predictive value of changes in the level of carbohydrate antigen 19‐9 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. (29th September 2020) - Zheng, Z.
Abstract: Aim: The aim of this work was to explore the predictive value of changes in the level of carbohydrate antigen 19‐9 (CA19‐9) after neoadjuvant chemoradiotherapy (nCRT) and after surgery in patients with locally advanced rectal cancer (LARC). Method: Patients with LARC who underwent nCRT and radical surgery (between 2011 and 2016) were divided into three groups according to pre‐nCRT and post‐nCRT CA19‐9 levels as follows: normal pre‐nCRT CA19‐9 (normal CA19‐9 group), elevated pre‐nCRT and normal post‐nCRT CA19‐9 (normalized group) and elevated pre‐nCRT and elevated post‐nCRT CA19‐9 (nonnormalized group). The pathological nCRT response criteria included ypCR and downstaging (ypStages 0–I). Recurrence‐free survival (RFS) and overall survival (OS) were analysed. Results: A total of 721 patients were identified. The normal CA19‐9 group was significantly associated with ypCR ( n = 159) and downstaging (n = 347) ( P < 0.05). The normalized group ( n = 76) had worse RFS and OS than the normal CA19‐9 group ( n = 622) and better RFS and OS than the nonnormalized group ( n = 23) (5‐year RFS 47.0% vs 66.9% vs 81.5%, P < 0.001; 5‐year OS 47.0% vs 75.4% vs 85.0%, P < 0.001). In multivariate analysis, CA19‐9 group and ypTNM stage were independent predictors of RFS and OS. Moreover, for the 23 patients with elevated post‐nCRT CA19‐9 levels, the RFS and OS of patients with normalized postoperative CA19‐9 levels were significantly better than those of patients with elevated postoperative CA19‐9 levels ( P < 0.05). Conclusion: Following nCRT, changes in the CA19‐9 level are a strong prognostic marker for long‐term survival, and they may be helpful in the selection of patients who prefer more conservative surgery after chemoradiotherapy.